SYNTHETIC CHEMISTRY SUPPORT FOR THE TDB MEDICINAL CHEMISTRY TEAM

为 TDB 药物化学团队提供合成化学支持

• 批准号: 10973001
• 负责人: RIANA FLETCHER
• 金额: $ 89.1万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-28 至 2024-09-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10973001
• 关键词: SYNTHETIC; CHEMISTRY; SUPPORT; TDB; MEDICINAL

The Therapeutic Development Branch (TDB) conducts translational research in human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline. A critical focus area for TDB is to efficiently identify preclinical development candidates for rare and neglected diseases. To accomplish this mission, TDB builds teams of chemists; pharmacologists; absorption, distribution, metabolism, and excretion (ADME)/pharmacokinetics (PK) experts; and toxicologists to work closely together to perform medicinal chemistry optimization on promising therapeutic lead compounds. TDB medicinal chemists engage contract research organizations (CROs) to support multiple lead generation and lead optimization projects in parallel. Currently, the TDB medicinal chemistry team is working on the following projects: 1) Development of malaria transmission-blocking drugs, and 2) Development of therapeutic candidates for rare ADCK3-amplified cancers.

治疗开发分支（TDB）在人类治疗开发中进行转化研究，旨在推动小分子和生物候选药物在药物开发管道中向前发展。TDB的一个关键重点领域是有效地识别罕见和被忽视疾病的临床前开发候选药物。为了完成这一使命，TDB建立了由化学家、药理学家、吸收、分布、代谢和排泄（ADME）/药代动力学（PK）专家和毒理学家组成的团队，他们密切合作，对有前景的治疗先导化合物进行药物化学优化。TDB药物化学家与合同研究组织（CRO）合作，并行支持多个潜在客户生成和潜在客户优化项目。目前，TDB药物化学团队正在开展以下项目：1）开发疟疾传播阻断药物，2）开发罕见ADCK 3扩增癌症的候选治疗药物。